194 related articles for article (PubMed ID: 15583737)
1. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
Gerotziafas GT; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Dec; 92(6):1296-302. PubMed ID: 15583737
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
3. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
[TBL] [Abstract][Full Text] [Related]
5. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
Linkins LA; Julian JA; Rischke J; Hirsh J; Weitz JI
Thromb Res; 2002 Sep; 107(5):241-4. PubMed ID: 12479885
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
[TBL] [Abstract][Full Text] [Related]
8. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174
[TBL] [Abstract][Full Text] [Related]
9. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation.
Ben-Hadj-Khalifa S; Hézard N; Almawi WY; Remy MG; Florent B; Mahjoub T; Nguyen P
Blood Coagul Fibrinolysis; 2011 Jul; 22(5):369-73. PubMed ID: 21577096
[TBL] [Abstract][Full Text] [Related]
10. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo.
Yau JW; Stafford AR; Liao P; Fredenburgh JC; Roberts R; Weitz JI
Blood; 2011 Dec; 118(25):6667-74. PubMed ID: 21937693
[TBL] [Abstract][Full Text] [Related]
13. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
[TBL] [Abstract][Full Text] [Related]
14. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats.
Iba T; Okamoto K; Ohike T; Tajirika T; Aihara K; Watanabe S; Kayhanian H
J Trauma Acute Care Surg; 2012 Jan; 72(1):177-82. PubMed ID: 22310127
[TBL] [Abstract][Full Text] [Related]
16. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
Bauer KA; Eriksson BI; Lassen MR; Turpie AG
Curr Opin Pulm Med; 2002 Sep; 8(5):398-404. PubMed ID: 12172443
[TBL] [Abstract][Full Text] [Related]
17. In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting time.
Jessen LR; Wiinberg B; Jensen AL; Kjelgaard-Hansen M; Jensen KH; Pedersen LB; Kristensen AT
Vet Clin Pathol; 2008 Dec; 37(4):363-72. PubMed ID: 19055570
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
Konstantinidis K; Gerasimidis T; Verdy E; Elalamy I; Samama MM; Gerotziafas GT
Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
[TBL] [Abstract][Full Text] [Related]
19. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
Schaden E; Schober A; Hacker S; Spiss C; Chiari A; Kozek-Langenecker S
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):256-61. PubMed ID: 20087172
[TBL] [Abstract][Full Text] [Related]
20. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
Bauer KA
Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
